Sygnature Discovery, Mironid®, and Peak Proteins to collaborate to discover new therapies for life-threatening and currently incurable kidney disease, ADPKD

1st February 2017 – Nottingham, UK – Sygnature Discovery, Mironid® Limited, a leader in cell signalling-directed drug discovery and Peak Proteins, have announced they will work closely together to discover new therapies against diseases driven by elevated cyclic AMP (cAMP), such as Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is a devastating, life-threatening and currently […]

Pelago Bioscience and Sygnature Discovery collaborate to Provide CETSA® based Target Engagement Assays

13th January 2017 – Nottingham, UK and Solna, Sweden – Sygnature Discovery today announced that it will collaborate with Pelago Bioscience, a Swedish biotech company to provide target engagement assays with Pelago’s patented Cellular Thermal Shift Assay (CETSA®) method. While target engagement has long been recognised as pivotal to targeted drug efficacy. Pelago’s CETSA method […]

Sygnature further enhances capabilities and services within the translational sciences.

14th December 2016 – Nottingham, UK – Sygnature Discovery has released a biology publication focusing on our collaboration with Corcept Therapeutics. This work highlights our biomarker validation work and reports the outcome of phase I QBR116598 study that was also recently presented at Sygnature by Quotient clinical. The publication, sets the scene to support further […]

Sygnature Discovery expands DMPK team with appointment of Dr. Edward Browne

12th October 2016 – Nottingham, UK – Sygnature announces the expansion of its DMPK team with the appointment of Dr Ed Browne as Associate Director of DMPK. Ed is an experienced drug discovery scientist who brings a thorough understanding of developing and prosecuting a lead optimisation strategy, having worked at GSK, Singapore for the last […]

Sygnature Discovery and Viramatix announce anti-viral drug discovery strategic alliance

5th October 2016 – Nottingham, UK and Kuala Lumpur, Malaysia – Sygnature Discovery Limited, the UK’s largest independent provider of integrated drug discovery resources and expertise, and Viramatix Sdn. Bhd., a biopharmaceutical company involved in the discovery of peptide based anti-viral therapeutics, today announced their ongoing collaboration on innovative anti-influenza therapeutics.   Influenza virus infection […]

Page 6 of 15« First...45678...Last »
Copyright © 2018 Sygnature Discovery

Website built by AtomicMedia - Design by Freestyle.